Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Annu Rev Med. 2024 Jan 29;75:99-111. doi: 10.1146/annurev-med-051022-043645.ABSTRACTWhen the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's c...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Judith L Heidebrink Henry L Paulson Source Type: research
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Annu Rev Med. 2024 Jan 29;75:293-306. doi: 10.1146/annurev-med-043021-033114.ABSTRACTDiabetic neuropathy is a highly prevalent complication of diabetes. It consists of a broad range of neuropathic conditions, such as distal symmetric polyneuropathy and various forms of autonomic neuropathies involving the cardiovascular, gastrointestinal, and urogenital systems. Prevention or diagnosis in early stages of disease is crucial to prevent symptomatic onset and progression, particularly in the absence of current disease-modifying therapies. In this review, we describe the four main types of diabetic neuropathy. We review current...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Brendan R Dillon Lynn Ang Rodica Pop-Busui Source Type: research
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
Annu Rev Med. 2024 Jan 29;75:49-66. doi: 10.1146/annurev-med-081522-031439.ABSTRACTProstate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-weight radioligands due to its extracellular portion. Successful targeting of PSMA began with the development of humanized J591 antibody. Due to their faster clearance compared to antibodies, small-molecule radioligands for targeted imaging and therapy of PC have been favored in recent development efforts. PSMA positron emission tomography (PET) imaging has higher diagno...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Lena M Unterrainer Jeremie Calais Neil H Bander Source Type: research
Complex Congenital Heart Disease in the Adult
Annu Rev Med. 2024 Jan 29;75:493-512. doi: 10.1146/annurev-med-050922-052324.ABSTRACTCongenital heart disease (CHD), a heterogeneous group of structural abnormalities of the cardiovascular system, is the most frequent cause of severe birth defects. Related to improved pediatric outcomes, there are now more adults living with CHD, including complex lesions, than children. Adults with CHD are at high risk for complications related to their underlying anatomy and past surgical palliative interventions. Adults with CHD require close monitoring and proactive management strategies to improve outcomes.PMID:38285514 | DOI:10.1146/...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Sarah A Goldstein Richard A Krasuski Source Type: research
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Annu Rev Med. 2024 Jan 29;75:99-111. doi: 10.1146/annurev-med-051022-043645.ABSTRACTWhen the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's c...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Judith L Heidebrink Henry L Paulson Source Type: research
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Annu Rev Med. 2024 Jan 29;75:293-306. doi: 10.1146/annurev-med-043021-033114.ABSTRACTDiabetic neuropathy is a highly prevalent complication of diabetes. It consists of a broad range of neuropathic conditions, such as distal symmetric polyneuropathy and various forms of autonomic neuropathies involving the cardiovascular, gastrointestinal, and urogenital systems. Prevention or diagnosis in early stages of disease is crucial to prevent symptomatic onset and progression, particularly in the absence of current disease-modifying therapies. In this review, we describe the four main types of diabetic neuropathy. We review current...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Brendan R Dillon Lynn Ang Rodica Pop-Busui Source Type: research
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
Annu Rev Med. 2024 Jan 29;75:49-66. doi: 10.1146/annurev-med-081522-031439.ABSTRACTProstate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-weight radioligands due to its extracellular portion. Successful targeting of PSMA began with the development of humanized J591 antibody. Due to their faster clearance compared to antibodies, small-molecule radioligands for targeted imaging and therapy of PC have been favored in recent development efforts. PSMA positron emission tomography (PET) imaging has higher diagno...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Lena M Unterrainer Jeremie Calais Neil H Bander Source Type: research
Complex Congenital Heart Disease in the Adult
Annu Rev Med. 2024 Jan 29;75:493-512. doi: 10.1146/annurev-med-050922-052324.ABSTRACTCongenital heart disease (CHD), a heterogeneous group of structural abnormalities of the cardiovascular system, is the most frequent cause of severe birth defects. Related to improved pediatric outcomes, there are now more adults living with CHD, including complex lesions, than children. Adults with CHD are at high risk for complications related to their underlying anatomy and past surgical palliative interventions. Adults with CHD require close monitoring and proactive management strategies to improve outcomes.PMID:38285514 | DOI:10.1146/...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Sarah A Goldstein Richard A Krasuski Source Type: research
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Annu Rev Med. 2024 Jan 29;75:99-111. doi: 10.1146/annurev-med-051022-043645.ABSTRACTWhen the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's c...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Judith L Heidebrink Henry L Paulson Source Type: research
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Annu Rev Med. 2024 Jan 29;75:293-306. doi: 10.1146/annurev-med-043021-033114.ABSTRACTDiabetic neuropathy is a highly prevalent complication of diabetes. It consists of a broad range of neuropathic conditions, such as distal symmetric polyneuropathy and various forms of autonomic neuropathies involving the cardiovascular, gastrointestinal, and urogenital systems. Prevention or diagnosis in early stages of disease is crucial to prevent symptomatic onset and progression, particularly in the absence of current disease-modifying therapies. In this review, we describe the four main types of diabetic neuropathy. We review current...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Brendan R Dillon Lynn Ang Rodica Pop-Busui Source Type: research
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
Annu Rev Med. 2024 Jan 29;75:49-66. doi: 10.1146/annurev-med-081522-031439.ABSTRACTProstate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-weight radioligands due to its extracellular portion. Successful targeting of PSMA began with the development of humanized J591 antibody. Due to their faster clearance compared to antibodies, small-molecule radioligands for targeted imaging and therapy of PC have been favored in recent development efforts. PSMA positron emission tomography (PET) imaging has higher diagno...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Lena M Unterrainer Jeremie Calais Neil H Bander Source Type: research
Complex Congenital Heart Disease in the Adult
Annu Rev Med. 2024 Jan 29;75:493-512. doi: 10.1146/annurev-med-050922-052324.ABSTRACTCongenital heart disease (CHD), a heterogeneous group of structural abnormalities of the cardiovascular system, is the most frequent cause of severe birth defects. Related to improved pediatric outcomes, there are now more adults living with CHD, including complex lesions, than children. Adults with CHD are at high risk for complications related to their underlying anatomy and past surgical palliative interventions. Adults with CHD require close monitoring and proactive management strategies to improve outcomes.PMID:38285514 | DOI:10.1146/...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Sarah A Goldstein Richard A Krasuski Source Type: research
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Annu Rev Med. 2024 Jan 29;75:99-111. doi: 10.1146/annurev-med-051022-043645.ABSTRACTWhen the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's c...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Judith L Heidebrink Henry L Paulson Source Type: research
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Annu Rev Med. 2024 Jan 29;75:293-306. doi: 10.1146/annurev-med-043021-033114.ABSTRACTDiabetic neuropathy is a highly prevalent complication of diabetes. It consists of a broad range of neuropathic conditions, such as distal symmetric polyneuropathy and various forms of autonomic neuropathies involving the cardiovascular, gastrointestinal, and urogenital systems. Prevention or diagnosis in early stages of disease is crucial to prevent symptomatic onset and progression, particularly in the absence of current disease-modifying therapies. In this review, we describe the four main types of diabetic neuropathy. We review current...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Brendan R Dillon Lynn Ang Rodica Pop-Busui Source Type: research
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
Annu Rev Med. 2024 Jan 29;75:49-66. doi: 10.1146/annurev-med-081522-031439.ABSTRACTProstate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-weight radioligands due to its extracellular portion. Successful targeting of PSMA began with the development of humanized J591 antibody. Due to their faster clearance compared to antibodies, small-molecule radioligands for targeted imaging and therapy of PC have been favored in recent development efforts. PSMA positron emission tomography (PET) imaging has higher diagno...
Source: Annual Review of Medicine - January 29, 2024 Category: General Medicine Authors: Lena M Unterrainer Jeremie Calais Neil H Bander Source Type: research
